Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model

Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model

Small Molecule RLR Agonist induced immunogenic tumor cell death in study

Seattle, WA, March 23, 2017 – Kineta, Inc., a biotechnology company focused on the translational development of novel therapies in immuno-oncology, today announced the discovery and characterization of several “hit to lead” small molecule compounds that activate interferon response factor 3 (IRF3) via RIG-I like receptor (RLR) pathways and demonstrate immune-mediated tumor regression in a murine colon carcinoma mouse model. Furthermore, mice in the study who demonstrated complete tumor regression to initial drug treatment were resistant to tumor re-challenge confirming an adaptive immune response in these animals. The findings were presented on March 22nd at the Keystone Symposia on Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology conference.

“Tumors exist in an immuno-suppressive environment and have many strategies of immune evasion. Kineta’s RLR agonists redirect the immune system to break tumor tolerance and elicit novel antigen-specific T-cell responses”, said Shawn Iadonato, CEO of Kineta. “These data are groundbreaking in cancer immuno-therapy as we successfully established tumor immunity in mice that had complete regression to an initial tumor.”

In this study, Kineta’s novel small molecule compounds demonstrated two immunomodulatory activities. First, they stimulate the RLR/IRF3 pathway in myeloid cells to induce the secretion of inflammatory chemokines/cytokines by human peripheral blood mononuclear cells and dendritic cells. Second, they induce immunogenic cell death in the CT26 colon carcinoma model. Inducing ICD in tumor cells results in the release of danger signals including ATP, HMGB1, and calreticulin that ultimately enhance immune recognition of the tumor.

“When ICD is elicited in tumor cells, they activate ‘kill-me’ markers such as ATP, HMGB1 and calreticulin. The immune system recognizes these markers and initiates an anti-tumor response”, said Kristin Bedard, VP Research and Development at Kineta. “In turning a cold tumor hot, we believe that Kineta’s RLR agonists can work in synergy with other immuno-therapies like checkpoint inhibitors to potentially enhance efficacy and patient survival.”


Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in chronic pain, immuno-oncology and infectious diseases. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum

Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum

Presentation focused on the Intersection of Inflammation and Immuno-Oncology

Seattle, WA October 4, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating therapies announced that its CEO, Dr. Shawn Iadonato, will participate on a panel presentation on immuno-oncology at the 15th annual BIO Investor Forum.

Dr. Iadonato will highlight Kineta’s Immuno-oncology program and be joined by leaders from other biopharmaceutical companies to discuss the development of new therapies in this emerging therapeutic area. The session entitled “The Intersection of Inflammation and Immuno-Oncology: Risks and Opportunities” is scheduled on October 18 from 9:00-10:15 PST. The conference is being held at the Westin St. Francis Hotel in San Francisco. Dr. Iadonato will be available for questions immediately following the presentation


The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering™ meetings

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in chronic pain, immuno-oncology and infectious diseases. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum

Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum

Presentation focused on novel treatment strategies

Seattle, WA, October 19, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating therapies announced that its CEO, Dr. Shawn Iadonato, joined a panel of leaders from other biopharmaceutical companies to discuss novel new treatment strategies in immuno-oncology. The panel presentation entitled “The Intersection of Inflammation and Immuno-Oncology: Risks and Opportunities” was conducted at the 15thannual BIO Investor Forum in San Francisco.

Dr. Iadonato highlighted details around Kineta’s small molecule compounds that may activate the RIG-I pathway to elicit immunogenic cell death in cancer tumor models. These novel compounds were identified using Kineta’s proprietary AVIiD™ screening platform which has also identified innate immune antivirals and vaccine adjuvants. “Cancer is typically not recognized as foreign by the body’s immune system which allows tumors to grow unchecked”, stated Kineta CEO Dr. Shawn Iadonato. “Kineta’s immune modulators activate the RIG-I pathway and may reprogram the immune system to recognize tumors as foreign and elicit neo-antigen T-cell responses to kill cancer. Priming the tumor microenvironment may also enable other therapies to be more effective when used in combination.”


The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering™ meetings

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in chronic pain, immuno-oncology and infectious diseases. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, anticipated drug effects in human subjects, and financial performance. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation: progress of drug development; ability to raise capital to fund drug development; clinical testing and regulatory approval; intellectual property protection and enforcement; our ability to recruit and retain scientists and other key personnel; competition from other drug development companies; and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta Secures NIAID Funding to Expand Testing of Immune Modulators

Kineta Secures NIAID Funding to Expand Testing of Immune Modulators

Funding to advance development of compounds that trigger the RIG-I pathway

Seattle, WA, July 12th, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs announced today it has received funding to advance the development of immune modulators.

This National Institute of Allergy and Infectious Disease (NIAID) awarded Kineta with a “direct to phase two” SBIR grant of up to $1.5M over two years. The funds will be used to advance the development of compounds that trigger the RIG-I pathway, activate IRF-3 and induce an antiviral response.

“We are pleased to broaden our longstanding collaboration with the NIAID to advance lead optimization of our novel immune modulating compounds”, said Dr. Shawn Iadonato, Kineta CEO. “These new lead compounds that were identified from Kineta’s AViiD™ screening platform hold tremendous potential to fill significant unmet medical needs in infectious diseases,” Dr. Iadonato added.

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.